Trientine tetrahydrochloride - GMP-Orphan

Drug Profile

Trientine tetrahydrochloride - GMP-Orphan

Latest Information Update: 29 Oct 2016

Price : $50

At a glance

  • Originator GMP-Orphan SAS
  • Class Ethylenediamines; Small molecules
  • Mechanism of Action Chelating agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatolenticular degeneration
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatolenticular degeneration

Most Recent Events

  • 27 Oct 2016 Chemical structure information added
  • 09 Sep 2016 Trientine tetrahydrochloride receives Orphan Drug status for Wilson's disease in USA before September 2016
  • 19 Mar 2015 Preclinical trials in Wilson's disease in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top